Molecular characterization of allergens and component-resolved diagnosis of IgE-mediated mango fruit allergy

Lan Zhao,Hanbing Xie,Xuefeng Wang,Meiling Liu,Tingting Ma,Wanyi Fu,Yuqi Wang,Dongya Wu,Yan Feng,Yi Liu,Shandong Wu,Xianqi Zhang,Huiying Wang,Fangmei Luo,Baohua Guo,Hongxia Wu,Yongmei Yu,Linglin Fu,Rudolf Valenta,Susanne Vrtala,Ronald van Ree,Xueyan Wang,Zhongshan Gao
DOI: https://doi.org/10.1111/all.15664
IF: 12.4
2023-01-01
Allergy
Abstract:R E FE R E N C E S 1. Simpson EL, Bieber T, GuttmanYassky E, et al. Two phase 3 trials of Dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):23352348. doi:10.1056/NEJMoa1610020 2. Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of Dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):4456. doi:10.1001/jamadermatol.2019.3336 3. Napolitano M, Fabbrocini G, Potestio L, et al. A 24weeks realworld experience of dupilumab in adolescents with moderatetosevere atopic dermatitis. Dermatol Ther. 2022;35(8):e15588. doi:10.1111/ dth.15588 4. Stingeni L, Hansel K, Antonelli E, et al. Atopic dermatitis in adolescents: effectiveness and safety of dupilumab in a 16week reallife experience during the COVID19 pandemic in Italy. Dermatol Ther. 2021;34(5):e15035. doi:10.1111/dth.15035 5. Stingeni L, Bianchi L, Antonelli E, et al. Moderatetosevere atopic dermatitis in adolescents treated with dupilumab: a multicentre Italian realworld experience. J Eur Acad Dermatol Venereol. 2022;36(8):12921299. doi:10.1111/jdv.18141 6. Hansel K, Patruno C, Antonelli E, et al. Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32week realworld experience during the COVID19 pandemic. Clin Exp Dermatol. 2022;47(1):165167. doi:10.1111/ced.14862
What problem does this paper attempt to address?